Gábor Rubovszky
A5016824553- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- PI3K/AKT/mTOR signaling in cancer
- Breast Implant and Reconstruction
- Breast Lesions and Carcinomas
- Cancer-related Molecular Pathways
- Cancer Genomics and Diagnostics
- Global Cancer Incidence and Screening
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Chronic Lymphocytic Leukemia Research
- Gastric Cancer Management and Outcomes
- PARP inhibition in cancer therapy
- Estrogen and related hormone effects
- Cancer Risks and Factors
- Nutrition, Genetics, and Disease
- Cancer Cells and Metastasis
- Lung Cancer Treatments and Mutations
- BRCA gene mutations in cancer
- Pharmacogenetics and Drug Metabolism
- Digital Imaging in Medicine
- Pancreatic and Hepatic Oncology Research
National Institute of Oncology
2016-2025
Országos Pszichiátriai és Neurológiai Intézet
2014-2024
Semmelweis University
2021-2024
Farmak (Czechia)
2023
National Institute of Criminology
2016-2020
Institut de Cancérologie de l'Ouest
2019
Aichi Cancer Center
2017-2019
Université Paris-Sud
2019
UCSF Helen Diller Family Comprehensive Cancer Center
2019
Sheba Medical Center
2017
PIK3CA mutations occur in approximately 40% of patients with hormone receptor (HR)–positive, human epidermal growth factor 2 (HER2)–negative breast cancer. The PI3Kα-specific inhibitor alpelisib has shown antitumor activity early studies.
Activation of the phosphatidylinositol-3-kinase (PI3K) pathway via PIK3CA mutations occurs in 28%-46% hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancers (ABCs) and is associated with poor prognosis. The SOLAR-1 trial showed that addition alpelisib to fulvestrant treatment provided statistically significant clinically meaningful progression-free survival (PFS) benefit PIK3CA-mutated, HR+, HER2- ABC.Men postmenopausal women ABC...
Abstract Addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant improved outcomes in patients with high-risk, early-stage, triple-negative breast cancer. However, whether the addition would improve estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER + /HER2 − ) cancer remains unclear. We conducted a double-blind, placebo-controlled phase 3 study (KEYNOTE-756) which previously untreated ER grade high-risk invasive (T1c-2 (≥2 cm), cN1–2 or T3–4,...
Improving the prognosis for patients with metastatic HR+/HER2- breast cancer remains an unmet need. Patients tumors that have progressed on endocrine therapy and/or are not eligible had limited treatment options beyond chemotherapy. Antibody-drug conjugates a novel and promising class in this setting. Datopotamab deruxtecan (Dato-DXd) consists of TROP2-directed humanized IgG1 monoclonal antibody attached via serum-stable cleavable linker to topoisomerase I inhibitor payload. TROPION-Breast01...
Abstract Background: KEYNOTE-756 (NCT03725059) is a global phase 3 study of neoadjuvant pembrolizumab or placebo + chemotherapy followed by adjuvant endocrine therapy (ET) in patients with early-stage high-risk ER+/HER2– breast cancer. Here, we report primary pCR results and residual cancer burden (RCB) outcomes. Methods: Eligible T1c-2 (≥2 cm) cN1-2 T3-4 cN0-2, centrally confirmed, grade 3, invasive ductal ER+/HER2− were randomized 1:1 to receive 200 mg Q3W placebo, both given paclitaxel QW...
PURPOSE The global, phase 3, open-label, randomized TROPION-Breast01 study assessed the trophoblast cell surface antigen 2–directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) versus investigator's choice of chemotherapy (ICC) in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) breast cancer. METHODS Adult patients with inoperable/metastatic HR+/HER2‒ cancer, who had disease progression on endocrine therapy, for whom therapy was...
Abstract Background: Hyperactivation of the phosphatidylinositol-3-kinase (PI3K) pathway can occur due to PIK3CA mutations, present in ~40% patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2—) ABC. SOLAR-1, a Phase 3 randomized, double-blind trial (NCT02437318), investigated efficacy and safety ALP (α-specific PI3K inhibitor) + FUL pts HR+, HER2— ALP+FUL met primary endpoint by significantly extending progression-free survival (PFS)...
Epidermal growth factor receptor (EGFR) is highly expressed in adenoid cystic carcinoma (ACC). The efficacy and toxicity of cetuximab with concomitant platinum-based chemoradio- or chemotherapy patients locally advanced metastatic ACC, respectively, was evaluated. Eligible (9 tumour 12 metastases) had positive EGFR expression. loading dose (400 mg m−2) followed by 250 m−2 per week. Locally tumours were irradiated (mean 65 Gy) treated cisplatin (75 m−2, intravenously). Patients metastases...
Concomitant intake of proton pump inhibitors (PPIs) may create drug-drug interactions, potentially impacting efficacy anticancer agents. In the phase III PALLAS trial, addition palbociclib capsules to standard adjuvant endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer did not improve invasive disease-free survival (iDFS). We explored whether concomitant use PPIs affected outcomes treated PALLAS.
Background Despite well-documented clinical differences across breast-cancer (BC) molecular subtypes and relevant changes in therapeutic interventions over the past decades, there remains a significant lack of up-to-date epidemiologic data real-world outcomes, particularly Central Eastern Europe. Methods This was nationwide, retrospective study using claims databases Hungarian National Health Insurance Fund (NHIF) that included patients who were newly diagnosed with BC between 2011 2020....
Abstract Background. The phase 3 PALLAS trial (NCT02513394) compared two years of the CDK4/6 inhibitor palbociclib with endocrine therapy provider choice, versus alone, as adjuvant treatment for patients Stage II-III hormone receptor-positive HER2-negative (HR+/HER2-) breast cancer. Genomic subtype (PAM50 intrinsic subtype) measured from whole-transcriptome RNA sequencing data was defined in protocol primary biomarker analysis prediction and prognosis. Clinical have been previously presented...
Introduction: Sentinel lymph node biopsy alone has become an acceptable alternative to elective axillary dissection in patients with clinically node-negative early-stage breast cancer. Approximately 70 percent of the undergoing surgery develop side effects caused by (axillary pain, shoulder stiffness, lymphedema and paresthesias). Aim: The current standard treatment is perform completion positive sentinel biopsy. However, randomized clinical trials versus irradiation failed show survival...